Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors von Adalsteinsson, Viktor A., Ha, Gavin, Freeman, Samuel S., Choudhury, Atish D., Stover, Daniel G., Parsons, Heather A., Gydush, Gregory, Reed, Sarah C., Rotem, Denisse, Rhoades, Justin, Loginov, Denis, Livitz, Dimitri, Rosebrock, Daniel, Leshchiner, Ignaty, Kim, Jaegil, Stewart, Chip, Rosenberg, Mara, Francis, Joshua M., Zhang, Cheng-Zhong, Cohen, Ofir, Oh, Coyin, Ding, Huiming, Polak, Paz, Lloyd, Max, Mahmud, Sairah, Helvie, Karla, Merrill, Margaret S., Santiago, Rebecca A., O’Connor, Edward P., Jeong, Seong H., Leeson, Rachel, Barry, Rachel M., Kramkowski, Joseph F., Zhang, Zhenwei, Polacek, Laura, Lohr, Jens G., Schleicher, Molly, Lipscomb, Emily, Saltzman, Andrea, Oliver, Nelly M., Marini, Lori, Waks, Adrienne G., Harshman, Lauren C., Tolaney, Sara M., Van Allen, Eliezer M., Winer, Eric P., Lin, Nancy U., Nakabayashi, Mari, Taplin, Mary-Ellen, Johannessen, Cory M., Garraway, Levi A., Golub, Todd R., Boehm, Jesse S., Wagle, Nikhil, Getz, Gad, Love, J. Christopher, Meyerson, Matthew

Volltext

Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer von Qu, Fangfang, Xie, Wanling, Nakabayashi, Mari, Zhang, Haitao, Jeong, Seong Ho, Wang, Xiaodong, Komura, Kazumasa, Sweeney, Christopher J, Sartor, Oliver, Lee, Gwo-Shu Mary, Kantoff, Philip W

Volltext

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer von MING YANG, WANLING XIE, SHARIFI, Nima, DOUGLAS FIGG, William, BALK, Steven, BROWN, Myles, TAPLIN, Mary-Ellen, OH, William K, MARY LEE, Gwo-Shu, KANTOFF, Philip W, MOSTAGHEL, Elahe, NAKABAYASHI, Mari, WERNER, Lillian, SUN, Tong, POMERANTZ, Mark, FREEDMAN, Matthew, ROSS, Robert, REGAN, Meredith

Volltext

Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer von Nakabayashi, Mari, Werner, Lilian, Courtney, Kevin D., Buckle, Geoffrey, Oh, William K., Bubley, Glen J., Hayes, Julia H., Weckstein, Douglas, Elfiky, Aymen, Sims, Danny M., Kantoff, Philip W., Taplin, Mary‐Ellen

Volltext

Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer von ROSS, Robert W, OH, William K, WANLING XIE, POMERANTZ, Mark, NAKABAYASHI, Mari, SARTOR, Oliver, TAPLIN, Mary-Ellen, REGAN, Meredith M, KANTOFF, Philip W, FREEDMAN, Matthew

Volltext

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer von Xie, Wanling, Regan, Meredith M, Buyse, Marc, Halabi, Susan, Kantoff, Philip W, Sartor, Oliver, Soule, Howard, Clarke, Noel W, Collette, Laurence, Dignam, James J, Fizazi, Karim, Paruleker, Wendy R, Sandler, Howard M, Sydes, Matthew R, Tombal, Bertrand, Williams, Scott G, Sweeney, Christopher J

Volltext

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer von Lohr, Jens G, Adalsteinsson, Viktor A, Cibulskis, Kristian, Choudhury, Atish D, Rosenberg, Mara, Cruz-Gordillo, Peter, Francis, Joshua M, Zhang, Cheng-Zhong, Shalek, Alex K, Satija, Rahul, Trombetta, John J, Lu, Diana, Tallapragada, Naren, Tahirova, Narmin, Kim, Sora, Blumenstiel, Brendan, Sougnez, Carrie, Lowe, Alarice, Wong, Bang, Auclair, Daniel, Van Allen, Eliezer M, Nakabayashi, Mari, Lis, Rosina T, Lee, Gwo-Shu M, Li, Tiantian, Chabot, Matthew S, Ly, Amy, Taplin, Mary-Ellen, Clancy, Thomas E, Loda, Massimo, Regev, Aviv, Meyerson, Matthew, Hahn, William C, Kantoff, Philip W, Golub, Todd R, Getz, Gad, Boehm, Jesse S, Love, J Christopher

Volltext

Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer von Nakabayashi, Mari, Regan, Meredith M., Lifsey, Deborah, Kantoff, Philip W., Taplin, Mary‐Ellen, Sartor, Oliver, Oh, William K.

Volltext

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and ove... von Sharma, Jaya, Gray, Kathryn P., Harshman, Lauren C., Evan, Carolyn, Nakabayashi, Mari, Fichorova, Raina, Rider, Jennifer, Mucci, Lorelei, Kantoff, Philip W., Sweeney, Christopher J.

Volltext

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer von Wang, Xiaodong, Harshman, Lauren C, Xie, Wanling, Nakabayashi, Mari, Qu, Fangfang, Pomerantz, Mark M, Lee, Gwo-Shu Mary, Kantoff, Philip W

Volltext

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) von Sweeney, Christopher, Nakabayashi, Mari, Regan, Meredith, Xie, Wanling, Hayes, Julia, Keating, Nancy, Li, Suhui, Philipson, Tomas, Buyse, Marc, Halabi, Susan, Kantoff, Philip, Sartor, A Oliver, Soule, Howard, Mahal, Brandon

Volltext

Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer von Nakabayashi, Mari, Oh, William K

Volltext

HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer von Hearn, Jason W.D., Xie, Wanling, Nakabayashi, Mari, Almassi, Nima, Reichard, Chad A., Pomerantz, Mark, Kantoff, Philip W., Sharifi, Nima

Volltext

Reply to clinical predictors of survival in men with castration‐resistant prostate cancer von Hayes, Julia H., Nakabayashi, Mari, Kantoff, Philip W.

Volltext

Clinical Predictors of Survival in Men with Castration-Resistant Prostate Cancer: Evidence That Gleason Score 6 Cancer Can Evolve to Lethal Disease von NAKABAYASHI, Mari, HAYES, Julia, TAPLIN, Mary-Ellen, LEFEBVRE, Patrick, LAFEUILLE, Marie-Helene, POMERANTZ, Mark, SWEENEY, Christopher, MEI SHENG DUH, KANTOFF, Philip W

Volltext

Correlation between time to prostate cancer metastasis and overall survival after androgen-deprivation therapy initiation von Valenca, Loana Bueno, Werner, Lillian, Xie, Wanling, Nakabayashi, Mari, Kantoff, Philip W., Pomerantz, Mark M

Volltext

Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer von Kantoff, Philip W., Wang, Xiaodong, Xie, Wanling, Nakabayashi, Mari, Pomerantz, Mark, Lee, Gwo-Shu Mary

Volltext

Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacies of abiraterone acetate and enzalutamide treatment in men with prostate cancer von Qu, Fangfang, Xie, Wanling, Nakabayashi, Mari, Zhang, Haitao, Jeong, Seong Ho, Wang, Xiaodong, Komura, Kazumasa, Sweeney, Christopher J, Sartor, Oliver, Lee, Gwo-Shu Mary, Kantoff, Philip W.

Volltext

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time t... von Sharma, Jaya, Gray, Kathryn P., Evan, Carolyn, Nakabayashi, Mari, Fichorova, Raina, Rider, Jennifer, Mucci, Lorelei, Kantoff, Philip W., Sweeney, Christopher J.

Volltext

The impact of statin use on the efficacy of abiraterone acetate in patients with castration‐resistant prostate cancer von Harshman, Lauren C., Werner, Lillian, Tripathi, Abhishek, Wang, Xiaodong, Maughan, Benjamin L., Antonarakis, Emmanuel S., Nakabayashi, Mari, McKay, Rana, Pomerantz, Mark, Mucci, Lorelei A., Taplin, Mary‐Ellen, Sweeney, Christopher J., Lee, Gwo‐Shu Mary, Kantoff, Philip W.

Volltext